Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASTION phase II trial of BrECADD in HIV-positive patients with advanced-stage classic Hodgkin lymphoma
2025-521749-26-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine and 1 more in classical Hodgkin lymphoma (cHL) and human immunodeficiency virus infection (HIV), sponsored by University of Cologne. Primary endpoints: TRMB rate, Acute non-hematological organ toxicity and 2 more. Planned start Sep 2026; status: authorised.
02
Drugs
brentuximab vedotinetoposidecyclophosphamidedoxorubicindacarbazine
03
Conditions
classical Hodgkin lymphoma (cHL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2025-521749-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521749-26-00.